An investigational small-molecule, nonpeptide oral GLP-1 receptor agonist significantly reduced weight in adults with obesity in the randomized ATTAIN-1 trial. At week 72, orforglipron at multiple ...

The first hints that Gregory Nelson might be having cognitive troubles were subtle. “Everyone who hits a certain age just ...

STORY: Novo Nordisk will test whether its future weight-loss drugs can treat a wide range of obesity-linked conditions. It’s already begun doing so with its blockbuster drug Wegovy. The Danish ...

Novo Nordisk , looking to turn around slowing growth of its blockbuster weight-loss drug Wegovy, plans to test whether its ...

Novo Nordisk is planning clinical trials to explore the potential of its weight-loss drugs in treating obesity-related conditions.

The fundamentals of the industry are driven by demographics, and broadening the scope provides a bit of growth opportunity,' ...

It's not as flashy as the other Apple Watches in this year's lineup, but the SE 3 will make a strong case for many buyers.

The Apple Watch SE 3 delivers two-day battery life, a top-of-the-line processor, an always-on display, and upgraded sensors ...

After nearly a week with the Apple Watch SE 3, I’ve found it to be the best Apple Watch for most people if you can live ...

Novo Nordisk plans to examine in clinical trials whether its future weight-loss drugs can treat a wide range of health ...